PADI2 and colorectal cancer: This interaction could be disrupted by PAD2-IN-1 (a selective PAD2 inhibitor), which impairs the crosstalk between colorectal cancer cells and METs and suppresses liver metastasis, thereby presenting a potential therapeutic strategy [52].